Michael B. Mason's most recent trade in Lilly(Eli) & Co was a trade of 8,023 Common Stock done at an average price of $345.1 . Disclosure was reported to the exchange on Feb. 10, 2023.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly | Michael B. Mason | EVP & Pres., Lilly Diabetes | Grant, award, or other acquisition of securities at price $ 345.12 per share. | 10 Feb 2023 | 8,023 | 39,284 (0%) | 0% | 345.1 | 2,768,898 | Common Stock |
Eli Lilly | Michael B. Mason | EVP & Pres., Lilly Diabetes | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2023 | 3,490 | 3,490 | - | - | Restricted Stock Unit | |
Eli Lilly | Michael B. Mason | EVP & Pres., Lilly Diabetes | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2023 | 6,690 | 34,196 (0%) | 0% | 0 | Common Stock | |
Eli Lilly | Michael B. Mason | EVP & Pres., Lilly Diabetes | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2023 | 6,690 | 0 | - | - | Restricted Stock Unit | |
Eli Lilly | Michael B. Mason | EVP & Pres., Lilly Diabetes | Payment of exercise price or tax liability using portion of securities received from the company at price $ 344.15 per share. | 01 Feb 2023 | 2,935 | 31,261 (0%) | 0% | 344.1 | 1,010,080 | Common Stock |
Eli Lilly | Michael B. Mason | Sr. VP & Pres., Lilly Diabetes | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 6,690 | 6,690 | - | - | Restricted Stock Unit | |
Eli Lilly | Michael B. Mason | Sr. VP & Pres., Lilly Diabetes | Grant, award, or other acquisition of securities at price $ 243.27 per share. | 09 Feb 2022 | 2,612 | 27,506 (0%) | 0% | 243.3 | 635,421 | Common Stock |
Eli Lilly | Michael B. Mason | Sr. VP & Pres., Lilly Diabetes | Grant, award, or other acquisition of securities at price $ 205.77 per share. | 08 Feb 2021 | 6,350 | 24,894 (0%) | 0% | 205.8 | 1,306,640 | Common Stock |